Treatment of progesterone deficiency and related conditions with a stable composition of progesterone and tocopherols
Patent 4439432 Issued on March 27, 1984. Estimated Expiration Date: 
March 22, 2002. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
March 22, 2002. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.InventorApplicationNo. 06/360587 filed on 03/22/1982US Classes:514/177, Oxygen double bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system514/171, With additional active ingredient514/843, Female (mammal)514/861, Eczema514/863, Psoriasis514/899, MENSTRUAL DISORDER514/970CONTAINING DESIGNATED INGREDIENT TO STABILIZE AN ACTIVE INGREDIENTExaminersPrimary: Roberts, Elbert L.Attorney, Agent or FirmInternational ClassesA61K 47/22 (20060101)A61K 31/57 (20060101) AbstractThis invention relates to the composition of a biologically compatible high concentration solution of progesterone, which is stable and non-toxic, and which can be used transdermally, orally, and in suppository and pessary form for the correction of progesterone deficiency states and other diseases.Other References
| |
